Axsome Therapeutics (AXSM) Income towards Parent Company: 2022-2025
Historic Income towards Parent Company for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to -$47.2 million.
- Axsome Therapeutics' Income towards Parent Company rose 26.89% to -$47.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$229.5 million, marking a year-over-year increase of 26.20%. This contributed to the annual value of -$287.2 million for FY2024, which is 20.05% down from last year.
- As of Q3 2025, Axsome Therapeutics' Income towards Parent Company stood at -$47.2 million, which was up 1.47% from -$47.9 million recorded in Q2 2025.
- Over the past 5 years, Axsome Therapeutics' Income towards Parent Company peaked at -$11.2 million during Q1 2023, and registered a low of -$98.6 million during Q4 2023.
- Its 3-year average for Income towards Parent Company is -$61.9 million, with a median of -$64.6 million in 2024.
- Its Income towards Parent Company has fluctuated over the past 5 years, first surged by 71.64% in 2023, then plummeted by 508.27% in 2024.
- Axsome Therapeutics' Income towards Parent Company (Quarterly) stood at -$61.2 million in 2022, then tumbled by 61.06% to -$98.6 million in 2023, then climbed by 24.05% to -$74.9 million in 2024, then increased by 26.89% to -$47.2 million in 2025.
- Its last three reported values are -$47.2 million in Q3 2025, -$47.9 million for Q2 2025, and -$59.4 million during Q1 2025.